Advances in the Use of N-Acetylcysteine in Chronic Respiratory Diseases

Antioxidants (Basel). 2023 Sep 2;12(9):1713. doi: 10.3390/antiox12091713.

Abstract

N-acetylcysteine (NAC) is widely used because of its mucolytic effects, taking part in the therapeutic protocols of cystic fibrosis. NAC is also administered as an antidote in acetaminophen (paracetamol) overdosing. Thanks to its wide antioxidative and anti-inflammatory effects, NAC may also be of benefit in other chronic inflammatory and fibrotizing respiratory diseases, such as chronic obstructive pulmonary disease, bronchial asthma, idiopathic lung fibrosis, or lung silicosis. In addition, NAC exerts low toxicity and rare adverse effects even in combination with other treatments, and it is cheap and easily accessible. This article brings a review of information on the mechanisms of inflammation and oxidative stress in selected chronic respiratory diseases and discusses the use of NAC in these disorders.

Keywords: COPD; IPF; N-acetylcysteine; asthma; chronic respiratory disorders; cystic fibrosis; oxidative stress; silicosis.

Publication types

  • Review